ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2565

Common Biomarker Elevations in Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis-Associated Interstitial Lung Disease

Karen Fernandez1, Tracy Doyle2, Lisa Harlow3, Ivan O. Rosas4 and Dana P. Ascherman5, 1Rheumatology, University of Miami Miller School of Medicine, Miami, FL, 2Medicine/Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 3Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, 4BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA, 5Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: interferons, interstitial lung disease, matrix metalloproteinase (MMP) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) which contributes to increased morbidity and mortality. Clinico-epidemiological data indicate some overlap in disease course between RA-ILD and idiopathic pulmonary fibrosis (IPF), particularly in subsets of RA-ILD patients with UIP-like pathology. We therefore evaluated levels of specific peripheral blood protein markers in patients with RA-ILD and IPF to determine molecular profiles indicative of shared disease pathogenesis.

Methods:  A cohort of patients that met ACR classification criteria for rheumatoid arthritis were enrolled and subclassified as having RA-no ILD versus RA-ILD (mild vs. advanced parenchymal lung abnormalities) based on high resolution computed tomography scans of the chest (HRCT). A cohort of patients with IPF was also enrolled through Brigham and Women’s Hospital. Standard solid phase enzyme-linked immunosorbent assays (ELISAs) were used to assess serum levels of matrix metalloproteinase 7 (MMP-7) and interferon-ϒ-inducible protein 10 (IP-10), which had previously been found to be significantly elevated in RA-ILD. Levels of serum biomarkers were compared using Mann U Whitney testing.

Results:  71 patients with RA were enrolled and classified as RA-no ILD (n=22) versus RA-ILD (n=49). Serum specimens were obtained from these patients as well as a comparator cohort of IPF patients (n=44). 72.7% (n=16) of patients in the RA-no ILD group, 63.3% (n=31) of patients in the RA-ILD and 40.9% (n=18) of patients in the IPF group were women. The average age of the patients in the RA-ILD and IPF groups were 65 and 66 years, respectively, vs 50 years in the RA-no ILD group (p=<0.0001). 63.6% (n=28) of the IPF patients, 55% (n=27 ) of the RA-ILD patients and 36.4% (n=8) of the RA-no ILD patients were smokers. ELISA-based measurement of serum MMP-7 revealed significantly increased levels in patients with RA-ILD and IPF (8.19 ng/ml vs 6.16 ng/ml, p=0.02). IP-10 levels were also significantly elevated in both RA-ILD and IPF patients (209.71 pg/ml vs 187.61 pg/ml, p=0.71). In contrast, patients with RA-no ILD had significantly lower levels of MMP-7 (2.98 ng/ml) and IP-10 (82.32 pg/ml) compared to patients with RA-ILD (MMP-7: p=<0.0001, IP-10: p=0.001) and patients with IPF (MMP7: p=<0.0001, IP-10: p=0.003).

Conclusion:  Serum levels of both MMP-7 and IP-10 were elevated in patients with IPF and RA-ILD relative to RA patients without evidence of ILD. This overlap in biomarker signatures encompassing both inflammatory (IP-10) and remodeling (MMP-7) pathways supports a possible link in pathogenesis that may suggest common therapeutic targets in RA-ILD and IPF.


Disclosure: K. Fernandez, None; T. Doyle, None; L. Harlow, None; I. O. Rosas, None; D. P. Ascherman, None.

To cite this abstract in AMA style:

Fernandez K, Doyle T, Harlow L, Rosas IO, Ascherman DP. Common Biomarker Elevations in Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis-Associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/common-biomarker-elevations-in-idiopathic-pulmonary-fibrosis-and-rheumatoid-arthritis-associated-interstitial-lung-disease/. Accessed January 31, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/common-biomarker-elevations-in-idiopathic-pulmonary-fibrosis-and-rheumatoid-arthritis-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences